Anti-hypertensive treatment in peripheral artery disease

Costas Tsioufis; Ioannis Andrikou; Gerasimos Siasos; Konstantinos Filis; Dimitrios Tousoulis

doi:10.1016/j.coph.2018.01.009

Anti-hypertensive treatment in peripheral artery disease

Curr Opin Pharmacol. 2018 Apr:39:35-42. doi: 10.1016/j.coph.2018.01.009. Epub 2018 Feb 22.

Authors

Costas Tsioufis¹, Ioannis Andrikou², Gerasimos Siasos², Konstantinos Filis³, Dimitrios Tousoulis²

Affiliations

¹ First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece. Electronic address: ktsioufis@hippocratio.gr.
² First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.
³ First Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece.

PMID: 29459079
DOI: 10.1016/j.coph.2018.01.009

Abstract

Peripheral artery disease (PAD) affects more than 200 million people worldwide. Hypertension has been related to increased risk of PAD. The treatment of elevated blood pressure (BP) in these patients is indicated to lower the cardiovascular risk with a BP goal of less than 130/80mmHg. Although there is no evidence that one class of antihypertensive medication or strategy is superior for BP lowering in PAD, the use of renin-angiotensin-system (RAS) inhibitors can be effective to reduce the cardiovascular risk. Beta-blockers (BBs) are not contraindicated. In the presence of carotid atherosclerosis, calcium-channel blockers (CCBs) and angiotensin-converting-enzyme inhibitors are recommended. In fibromuscular dysplasia the treatment of choice is percutaneous renal angioplasty. In renal artery disease optimal medical therapy includes RAS inhibitors, CCBs, BBs and diuretics.

Publication types

Review

MeSH terms

Adrenergic beta-Antagonists / therapeutic use*
Antihypertensive Agents / therapeutic use*
Carotid Artery Diseases / drug therapy*
Humans
Peripheral Arterial Disease / drug therapy*
Renal Artery*

Substances

Adrenergic beta-Antagonists
Antihypertensive Agents